Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
109 participants
OBSERVATIONAL
2021-07-02
2029-06-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Early Detection of Lung Cancer
NCT03181256
Prospective Multicenter Cohort Study for the Development and Evaluation of Risk Stratification Tools for Lung Cancers and Their Postoperative Recurrences Using Multimodal Clinical, Radiological, Tissue and Longitudinal Biological Phenotyping Among People at Risk of Lung Cancer
NCT07042867
Understanding Non-small Cell Lung Cancer Patient Characteristics, Treatment Patterns and Outcomes
NCT07215026
Community-Based Engagement to Improve Lung Cancer Screening and Outcomes: The "Our Lungs Our Health" Study
NCT06909981
A Prognosis and Predicting Genetic Study of Lung Cancer
NCT03234179
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. To assess the frequency of germline cancer susceptibility mutations in affected and unaffected individuals who have a personal or family history suggestive of high lung cancer risk.
EXPLORATORY OBJECTIVES:
I. To assess the frequency of abnormal radiographic findings in high-risk individuals unaffected with cancer who undergo low-dose computed tomography (CT) screening.
II. Use patient survey and medical record data to explore the associations between social determinants of health, biological risk factors, family history and lung cancer incidence.
III. To determine the sensitivity and specificity of liquid biopsy for detection of lung cancer in a never-smoking population.
OUTLINE:
Participants complete a survey over 40-45 minutes at baseline and undergo collection of blood samples at a scheduled clinical or research blood draw. Participants' medical records are also reviewed. Participants not diagnosed with lung cancer (i.e. "unaffected"), undergo a low-dose computerized tomography (CT) scan over 20 minutes.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Observational (survey, biospecimen, medical record, CT)
Participants complete a survey over 40-45 minutes at baseline. Participants' medical records are also reviewed. Participants who have lung cancer but have not undergone treatment and participants not diagnosed with lung cancer (i.e., "unaffected"), undergo collection of blood samples at a scheduled clinical or research blood draw. Participants not diagnosed with lung cancer (i.e. "unaffected"), undergo a low-dose CT scan over 20 minutes.
Biospecimen Collection
Undergo collection of blood samples
Computed Tomography
Undergo low-dose CT
Electronic Health Record Review
Review of medical records
Survey Administration
Complete survey
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Biospecimen Collection
Undergo collection of blood samples
Computed Tomography
Undergo low-dose CT
Electronic Health Record Review
Review of medical records
Survey Administration
Complete survey
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age \>= 18 years
* Willing to have about 30 mL of blood (approximately 2 tablespoons) drawn during the aspiration visit
* Speak English, Spanish, or Mandarin
* Lung cancer patients: meeting at least one of the following criteria:
* Be a never-smoker with lung cancer (excludes atypical/typical carcinoid and small cell tumors)
* Be diagnosed with lung cancer =\< 50 years of age
* Have a germline alteration known/suspected to be associated with elevated lung cancer risk
* Have a strong family history of lung cancer (\>= one first, second or third degree relative with never-smoking lung cancer, \>= three first, second or third degree relative with lung cancer in one lineage \[side of the family\], \>= one first, second or third degree relative diagnosed with lung cancer under the age of 50. Patients may also be considered eligible if they meet the family history criteria in part and have a truncated family structure \[e.g., only one first and one second degree relative with lung cancer in a small family\])
* Unaffected patients (i.e., those without a lung cancer diagnosis and other cancer diagnosis for the past 5 years) who are at least 50 years of age or at most age 10 years younger than the first case of lung cancer in the family, meeting at least one of the following criteria:
* Have a germline alteration known/suspected to be associated with elevated lung cancer risk
* Have a strong family history of lung cancer (\>= one first, second or third degree relative with never-smoking lung cancer, \>= three first, second or third degree relative with lung cancer in one lineage \[side of the family\], \>= one first, second or third degree relative diagnosed with lung cancer under the age of 50. Patients may also be considered eligible if they meet the family history criteria in part and have a truncated family structure \[e.g., only one first and one second degree relative with lung cancer in a small family\])
* Of East Asian descent with any family history of lung cancer
* Documented informed consent of the participant
Exclusion Criteria
* Patients who fall under the unaffected cohort criteria but received chest imaging (except chest x-ray) within the last year
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
City of Hope Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Stacy W Gray
Role: PRINCIPAL_INVESTIGATOR
City of Hope Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
City of Hope Medical Center
Duarte, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2021-05881
Identifier Type: REGISTRY
Identifier Source: secondary_id
19594
Identifier Type: OTHER
Identifier Source: secondary_id
19594
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.